Progesterone Receptor-negative Breast Cancer Completed Phase 2 Trials for Saracatinib (DB11805)

IndicationStatusPhase
DBCOND0028547 (Progesterone Receptor-negative Breast Cancer)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00559507Saracatinib in Treating Patients With Metastatic or Locally Advanced Breast Cancer That Cannot Be Removed By SurgeryTreatment